Hepatocellular Carcinoma
Conditions
Brief summary
The primary endpoint is the BOR of confirmed CR or confirmed PR per RECIST 1.1 as determined by investigators at any time prior to subsequent anticancer therapy.
Detailed description
The secondary endpoints are DoR by investigators, PFS by investigators, and OS., PFS by investigators: The time from randomization until the first documentation of progressive disease according to RECIST 1.1 as determined by investigators or death from any cause, whichever occurs first., OS: The time from randomization until death from any cause.
Interventions
Sponsors
Abbvie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the BOR of confirmed CR or confirmed PR per RECIST 1.1 as determined by investigators at any time prior to subsequent anticancer therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are DoR by investigators, PFS by investigators, and OS., PFS by investigators: The time from randomization until the first documentation of progressive disease according to RECIST 1.1 as determined by investigators or death from any cause, whichever occurs first., OS: The time from randomization until death from any cause. | — |
Countries
France, Italy, Spain
Outcome results
None listed